Principal Financial Group
CERE

Principal Financial Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Principal Financial Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,146
Closed -$497K – 2440
2024
Q2 		$497K Sell
12,146
-15,085
-55% -$628K ﹤0.01% 1961
2024
Q1 		$1.15M Buy
27,231
+114
+0.4% +$4.79K ﹤0.01% 1850
2023
Q4 		$1.15M Buy
27,117
+430
+2% +$12.4K ﹤0.01% 1824
2023
Q3 		$583K Buy
26,687
+115
+0.4% +$2.88K ﹤0.01% 1918
2023
Q2 		$845K Sell
26,572
-1,607
-6% -$49.3K ﹤0.01% 1865
2023
Q1 		$687K Sell
28,179
-1,714
-6% -$50.3K ﹤0.01% 1910
2022
Q4 		$943K Buy
29,893
+4,597
+18% +$130K ﹤0.01% 1865
2022
Q3 		$715K Sell
25,296
-13
-0.1% -$387 ﹤0.01% 1894
2022
Q2 		$669K Buy
25,309
+1,075
+4% +$30.5K ﹤0.01% 1997
2022
Q1 		$849K Sell
24,234
-92
-0.4% -$2.69K ﹤0.01% 2005
2021
Q4 		$788K Buy
24,326
+15,916
+189% +$562K ﹤0.01% 2033
2021
Q3 		$248K Buy
+8,410
New +$236K ﹤0.01% 2369

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Principal Financial Group's CERE Position: Q3 2024 in Review

Principal Financial Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 12,146 shares — an estimated $497K sold.

Principal Financial Group first reported a position in CERE in Q3 2021 and held it in 12 quarters. The position peaked at $1.15M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Principal Financial Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 12,146 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $497K.
  • Principal Financial Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • Principal Financial Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.15M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.